US 8986701
Enzyme prodrug cancer therapy selectively targeted to tumor vasculature and methods of production and use thereof
granted A61KA61K38/16A61K38/51
Quick answer
US patent 8986701 (Enzyme prodrug cancer therapy selectively targeted to tumor vasculature and methods of production and use thereof) held by The Board of Regents of the University of Oklahoma expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Oklahoma
- Grant date
- Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K38/16, A61K38/51, A61K39/0011, A61K45/06